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Antimicrobial activity of BMS 284756, a novel des-fluoro (6)
quinolone and seven fluoroquinolones against Streptococcus
pneumoniae
BMS 284756 is a novel des-fluoro (6) quinolone that demon-
strates broad activity against a wide range of clinically important
pathogens, including Gram-positive and Gram-negative aero-
bes and anaerobes [1]. Because of the enhanced activity of
recently released fluoroquinolones against Gram-positive bac-
teria along with the increasing prevalence of penicillin non-
susceptible strains of Streptococcus pneumoniae, this study was
undertaken to evaluate and compare the in vitro activity of
BMS 284756 compared to that of seven other fluoroquino-
lones. These antibiotics were tested against 199 clinical isolates
of S. pneumoniae from a United States regional surveillance
study.
Strains of S. pneumoniae (n¼ 199) isolated during 1998–99
from a 10-hospital health care system in south-eastern Michigan
were collected from clinical specimens and stored at 70 8C.
Only one isolate per patient was included, thus excluding dupli-
cation. The isolates were collected from blood (66 patients),
respiratory secretions (132 patients) and cerebrospinal fluid
(one patient). Break-points used for penicillin susceptibility
were divided into three categories according to NCCLS guide-
lines: penicillin susceptible (PSSP) minimal inhibitory concen-
tration (MIC) 0.06 mg/L; intermediate susceptibility (PISP)
MIC¼ 0.12–1.0 mg/L, and penicillin resistant (PRSP) MIC
2.0 mg/L [2].
Antimicrobial agents including standard powders were pro-
vided by the manufacturer and included: BMS 284756
(Bristol-Myers Squibb, Princeton, NJ), ciprofloxacin, moxi-
floxacin (Bayer Corp., West Haven, CT) clinafloxacin, spar-
floxacin (Parke Davis, Ann Arbor, MI), grepafloxacin
(Glaxo-Wellcome Research, Triangle Park, NC), levofloxacin
(Ortho-McNeil, Raritan, NJ), and trovafloxacin (Pfizer, Groton,
CT). The powders were used to prepare stock antibiotic
dilutions as outlined in the NCCLS standards [2].
MICs were determined by microdilution broth assay, using
cation-adjusted Mueller Hinton broth supplemented with 2–
5% lysed horse blood (Cleveland Scientific, Bath, OH, USA).
Suspensions were prepared from an 18-h pure culture in saline
adjusted to a 0.5 McFarland standard with a final inoculum of
5 105 colony-forming units (CFU)/mL. Microtiter plates
were incubated at 35 8C for 20–24 h in ambient air. The
standard quality control strain S. pneumoniae ATCC 49619
was included in each run.
The determined susceptibility data for each of the antimi-
crobial agents tested are summarised in Table 1. BMS 284756
demonstrated the greatest in vitro activity with the lowest
MIC90. There were no isolates resistant to any of the quinolones
except for ciprofloxacin where 10 isolates (5%) were nonsus-
ceptible at a ciprofloxacin concentration of 4 mg/L. For the 10
isolates with ciprofloxacin MICs4 mg/L, the MIC90 for BMS
284756 was identical to the MIC90 for the 199 isolates.
When evaluating quinolone activity relative to penicillin
susceptibility, isolates categorised into groups as PSSP (54),
PISP (78) and PRSP (67) showed no difference for BMS
284756 or any of the other fluoroquinolones tested.
There have been 10 fluoroquinolones released since cipro-
floxacin was introduced in 1987 [3]. Recently, the newest
agents have been advocated for the empiric treatment of
respiratory tract infections due to the increase in resistance to
penicillin and the need to identify alternative classes of anti-
microbial agents with enhanced activity against S. pneumoniae.
These agents can also be useful in the treatment of the patient
allergic to b-lactam agents. With the advantages already enum-
erated, pharmaceutical manufacturers have promoted this class
of drugs as effective for the treatment of respiratory tract
infections due to S. pneumoniae. However, the clinician has
been given data limited to each drug alone or compared to only
a few fluoroquinolones to assess the relative activity of these
agents in order to select the most effective agent. This study
determined the potency of a novel des-fluoro (6) quinolone,
BMS 284756 and seven other quinolones by determining their
MICs for recent isolates of S. pneumoniae.
When evaluating potency, the most recently developed
fluoroquinolones clearly demonstrate superior activity com-
pared to earlier agents such as, ciprofloxacin and levofloxacin.
BMS 284756 is a novel fourth generation fluoroquinolone with
excellent activity against S. pneumoniae as seen in this study.
BMS 284756 was unaffected by decreased susceptibility to other
quinolones, though only 5% of the isolates tested in this study
were nonsusceptibile to ciprofloxacin at a concentration of
4 mg/L. A small number of isolates were tested in this study
with decreased ciprofloxacin susceptibility and thus any inter-
pretation must be made cautiously. Chen et al. have emphasised
the increase in the prevalence of pneumococci with reduced
susceptibility to fluoroquinolones in Canada, probably as a
Table1 Susceptibility of199Streptococcus pneumoniae clinical isolates and
pharmacodynamics for the eight fluoroquinolones tested
MIC (mg/L)
Antimicrobial
agent Range MIC50 MIC90
BMS 284756 0.03^0.13 0.03 0.06
Moxifloxacin 0.03^2 0.13 0.13
Trovafloxacin 0.03^64 0.13 0.25
Clinafloxacin 0.03^0.25 0.06 0.13
Levofloxacin 0.03^64 0.5 1.0
Grepafloxacin 0.03^2 0.13 0.25
Sparfloxacin 0.03^1 0.25 0.50
Ciprofloxacin 0.03^8 1.0 2.0
MIC, minimal inhibitory concentration.
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result of selective pressure from the increased use of fluoroqui-
nolones [4].
Finally, a balance between efficacy and toxicity must enter
into the consideration of selection of any antimicrobial agent. In
spite of good in vitro activity, grepafloxacin, sparfloxacin, tema-
floxacin and trovafloxacin have had toxicities arise that have
either severely limited these agents or completely eliminated
them from clinical consideration.
As shown by previous studies with smaller number of isolates,
BMS 284756 demonstrated greater in vitro potency when
compared to other fluoroquinolones. This study extends the
observations from studies in Japan by including a larger number
of isolates as well as comparative agents [1].
In summary, whereas all the new fluoroquinolones tested in
this study demonstrated enhanced in vitro activity compared to
ciprofloxacin and levofloxacin, BMS 284756 demonstrated the
greatest in vitro activity.
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Fatal Roseomonas gilardii bacteremia in a patient with refractory
blast crisis of chronicmyeloid leukemia
In January 2000, a 31-year-old male with refractory blast crisis
of chronic myeloid leukemia (CML) since July 1998 attended
the hematology clinic with fever and productive cough,
3 months following implantation of a Hickman catheter.
Although chemotherapy had achieved morphologic remission,
cytogenetic studies showed an approximate 50% positivity for
the Philadelphia chromosome, and in October 1999, bone
marrow aspirate revealed residual leukemia with 30% blasts.
Owing to the refractory nature of this disease and the con-
sequent poor prognosis for recovery, the patient was managed
symptomatically and with palliative chemotherapy.
On examination, the patient was pale and lethargic, with a
temperature of 40.5 8C, a tachycardia of 120 beats/min, and a
blood pressure of 140/90 mmHg. Chest auscultation revealed
diffuse expiratory wheeze and crepitations at the right base. The
abdomen was tense but non-tender. The patient was admitted
and started empirically on piperacillin–tazobactam 4.5 g
8-hourly and gentamicin 7.5 mg/kg per day. Shortly after the
first dose of gentamicin, he developed severe abdominal pain
which was attributed to gentamicin, which was then substituted
with vancomycin 1 g 12-hourly. On admission, the total leu-
kocyte count was 11.1 109/L, and the neutrophil count was
2.94 109/L. During the preceding year, typical values for total
leukocyte count were <2.5 109/L, and those for the neu-
trophil count were<0.5 109/L. Blood culture sets, from both
Hickman and peripheral lines, were positive for Gram-negative
bacilli after 4 days of incubation (BacTAlert, Organon-Teknika,
Boxtel, the Netherlands). As the pyrexia was unresponsive to
piperacillin–tazobactam, this was substituted with ceftazidime
2 g 8-hourly on day 3, which led to rapid resolution. Further
blood cultures drawn from the Hickman line on day 3 following
admission grew a similar organism. Vancomycin and ceftazi-
dime were continued for a total of 5 days, after which the patient
was discharged home on oral ciprofloxacin and clarithromycin
for his residual chest infection. One week later he presented in
the outpatient department with a low-grade pyrexia and per-
sistent non-productive cough. Blood cultures drawn from the
Hickman line at this time again grew a Gram-negative bacillus
after 4 days of incubation. However, following routine blood
and platelet transfusion, the patient refused further intervention
and was discharged home. Two weeks later he died, following a
pyrexial episode.
On all three occasions, subculture of blood culture fluid
revealed pink-pigmented colonies which grew after 48 h of
incubation at 37 8C on Columbia blood agar plates. These
organisms were Gram-negative bacilli, arranged in pairs, which
grew on MacConkey agar, and were positive for catalase and
oxidase. The isolates gave positive reactions for urea hydrolysis
and oxidation of glucose, arabinose and citrate. However, the
isolates tested negative for nitrate reduction, indole production,
arginine dehydrolase, gelatinase and b-galactosidase. The iso-
lates were also negative for oxidation of mannose, maltose,
mannitol and N-acetylglucosamine (API 20E and API 20NE
biochemical strip, BioMe´rieux, La Balme-Les-Grottes, France).
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